Advanced BioChemicals (ABC) offer HOOC-PEG-OH with MW 2kDa, 3.5 kDa, 5kDa, 10kDa and 20kDa, in 100mg, 500mg, 1g and 5g packing sizes. Different MW of HOOC-PEG-OH products may be available by custom synthesis, please email us at tech@advancedbiochemicals.com for details. Advanced BioChemicals (ABC) also provide repackaging services, please contact us at sales@advancedbiochemicals.com for a free quote.
| MW | 2K, 3.5K, 5K, 10K, 20K |
|---|---|
| Pack Size | 1g, 5g |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
)懂得一些道理或知识.
让世界充满爱不仅是付出,还可以是回报,回报你所关爱的人.
我记得有首歌曲,它的意思是爸爸妈妈辛苦了一天,回到家,帮他们拿拖鞋,帮他们倒杯茶,这是感
恩.老师批改作业累了,可以给他们捶捶背,当学习获得了一定的成功,老师会感到欣慰,这是感恩.当
同学遭遇困难时,你可以去用尽全力地安慰帮助他(她),使他(她)能够解决困难,克服困难,变得快
乐.这也是感恩.
作者、斯坦福大学医学中心的梅斯勒(AnnaH.Messner)和同事解释,有多个研究曾检查了在扁桃体切除手术前使用类固醇类药的情况,但得到的结果不一。据他们在8月《耳鼻喉、头、颈外科文献》(ArchOtolaryngolHeadNeckSurg2004;130:917-921)上发表的论文说,他们对这种病人进行了一项最大的前瞻性、随机、双盲研究。
共219名9个月至12岁的参试者被随机分为或用地塞米松1mg/kg,最大剂量至50mg(n=106),或用安慰剂(n=113)。在药物组中,62人进行的扁桃体切除术采用的是电烧烙法,44人采用的是锐性分离。安慰剂两种方法分别为56人和57人。术后第一天,类固醇组医生评定的Wong-Baker可视模拟量表上的疼痛分平均为4.4,安慰剂组5.3(p<0.001);前组家长评估的疼痛分(p=0.002)和病儿自己评估的疼痛分((p=0.002))也明显更低。类固醇组有1.2次呕吐发作,安慰剂组2.1次(p=0.02),前组也更快地恢复了正常进食(=0.004)。另外,作者还发现,进行锐性分离的病人使用类固醇受益最大,医生和家长评估的疼痛分显著低于电烧烙组。
“我们的研究结果支持在进行扁桃体手术时以1mg/kg的剂量IV地塞米松”,研究者总结。
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.

